248 related articles for article (PubMed ID: 25209137)
41. The relationship among proton pump inhibitors, bone disease and fracture.
Targownik LE; Leslie WD
Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
[TBL] [Abstract][Full Text] [Related]
42. The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors.
Fleishman N; Richardson T; Attard T
J Pediatr Gastroenterol Nutr; 2020 Jun; 70(6):815-819. PubMed ID: 32443038
[TBL] [Abstract][Full Text] [Related]
43. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.
Yang SD; Chen Q; Wei HK; Zhang F; Yang DL; Shen Y; Ding WY
Int J Clin Exp Med; 2015; 8(4):4899-910. PubMed ID: 26131063
[TBL] [Abstract][Full Text] [Related]
44. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
Labenz C; Wörns MA; Adarkwah CC; Galle PR; Schattenberg JM; Kostev K
Aliment Pharmacol Ther; 2020 Sep; 52(6):1042-1050. PubMed ID: 32729625
[TBL] [Abstract][Full Text] [Related]
45. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
46. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.
Kanno T; Moayyedi P
Curr Gastroenterol Rep; 2019 Dec; 21(12):65. PubMed ID: 31807948
[TBL] [Abstract][Full Text] [Related]
47. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board.
Jarchow-Macdonald AA; Mangoni AA
Geriatr Gerontol Int; 2013 Oct; 13(4):1002-9. PubMed ID: 23506515
[TBL] [Abstract][Full Text] [Related]
48. The risks of PPI therapy.
Moayyedi P; Leontiadis GI
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(3):132-9. PubMed ID: 22330810
[TBL] [Abstract][Full Text] [Related]
49. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
Maléth J; Hegyi P
Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
[TBL] [Abstract][Full Text] [Related]
50. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
[TBL] [Abstract][Full Text] [Related]
51. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study.
Liu Y; Zhu X; Li R; Zhang J; Zhang F
BMJ Open; 2020 Nov; 10(11):e040473. PubMed ID: 33243802
[TBL] [Abstract][Full Text] [Related]
52. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
Lenihan CR; Sukumaran Nair S; Vangala C; Ramanathan V; Montez-Rath ME; Winkelmayer WC
Am J Kidney Dis; 2017 May; 69(5):595-601. PubMed ID: 27866965
[TBL] [Abstract][Full Text] [Related]
53. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
54. [Long-term use of proton pump inhibitors: who needs prophylaxis?].
Scheurlen M
Internist (Berl); 2013 Mar; 54(3):366-72. PubMed ID: 23404267
[TBL] [Abstract][Full Text] [Related]
55. [Impact of an evaluation of the professional practices on the relevance of proton pump inhibitors prescriptions pertinence at the hospital].
Daumas A; Garros E; Mendizabal H; Gayet S; Bernard F; Bagnères D; Demoux AL; Rossi P; Villani P; Granel B
Rev Med Interne; 2018 Aug; 39(8):618-626. PubMed ID: 29628172
[TBL] [Abstract][Full Text] [Related]
56. Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections.
Laria A; Zoli A; Gremese E; Ferraccioli GF
Reumatismo; 2011 Mar; 63(1):5-10. PubMed ID: 21509344
[TBL] [Abstract][Full Text] [Related]
57. Proton pump inhibitors and osteoporosis.
Andersen BN; Johansen PB; Abrahamsen B
Curr Opin Rheumatol; 2016 Jul; 28(4):420-5. PubMed ID: 27224743
[TBL] [Abstract][Full Text] [Related]
58. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
59. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
60. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
